关于“TetraLogic暂时停了birinapant乙肝试验注册股暴跌 ”

x321

开不开发得出新药从K线也能看出？

qazwsx1234

从股票的角度，如果从中国股市来讲，有时候上市公司会为了配合主力建仓发布一些利空消息，比如年报或者季报亏损很多，打压建仓，这样主力就可以在低位建仓，这个我看到过很多这样的公司，比如人人乐，或者，荣信股份，这些都是这样做的，净利润出现大幅亏损，其实那不叫亏损他把一年的费用都算到一个季度，这样这个公司当然大亏了，以后就利润大大的。

qazwsx1234

股票的上涨下跌有机构的博弈在里面，和消息关系不大，主力就是消息的制造者，上市公司有时候也会配合，你看白云山和重庆啤酒这两只股就知道了，他们都是搞hbv治疗性疫苗的。

hao2014

股市高手来了

中国先生ws

会不会是公司为了更多的利益做空了股市才暂停实验的  这个药毕竟已经做过1期实验  副作用都是知道的  只因为可逆的面瘫就暂停太谨慎了吧  而且在hcc的实验中肯定有很多hbver  副作用肯定都知道

qazwsx1234

有这个可能

StephenW

回复 中国先生ws 的帖子

Birinapant 从来没有使用在HCC患者在临床试验.

hao2014

StephenW 发表于 2015-5-9 22:43
回复 中国先生ws 的帖子

Birinapant 从来没有使用在HCC患者在临床试验.

这个怎么说呢

英文网站我没去过

国内相关报道中说过，这个药物针对肝癌患者实验进入临床2期了，没说具体怎么样

希望英文高手去FDA网站核实

StephenW

回复 hao2014 的帖子

Recruiting         Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
Conditions:         Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML)
Interventions:         Drug: birinapant;   Drug: Azacitidine;   Drug: Placebo
2         Active, not recruiting         Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B
Condition:         Hepatitis B
Interventions:         Drug: Antiviral Therapy (tenofovir or entecavir);   Drug: Birinapant;   Drug: Placebo (for birinapant)
3         Active, not recruiting         Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
Condition:         Myelodysplastic Syndrome
Interventions:         Drug: TL32711;   Drug: 5-Azacitidine
4         Recruiting         Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Conditions:         Relapsed Epithelial Ovarian Cancer;   Relapsed Primary Peritoneal Cancer;   Relapsed Fallopian Tube Cancer
Interventions:         Drug: Birinapant;   Drug: Conatumumab
5         Completed         Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors
Condition:         Cancer
Intervention:         Drug: TL32711
6         Completed
Has Results         Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Conditions:         Epithelial Ovarian Cancer;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Intervention:         Drug: Birinapant (TL32711)
7         Terminated         Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Condition:         Unspecified Adult Solid Tumor, Protocol Specific
Interventions:         Drug: Smac mimetic TL32711;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: biopsy
8         Withdrawn         18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
Conditions:         Ovarian Neoplasms;   Ovarian Cancer;   Fallopian Tube Neoplasms;   Fallopian Tube Cancer
Interventions:         Drug: [18F]-CP18;   Procedure: PET/ CT
9         Completed         Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Condition:         Cancer
Intervention:         Drug: TL32711
10         Completed         A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia
Condition:         Acute Myelogenous Leukemia
Intervention:         Drug: TL32711

tonychant

再次证明人类征服不了乙肝，这一类根治药物都是在临床二期前就戛然而止，留给大家一次又一次希望再失望，希望再失望直至绝望的痛苦经历。